These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

291 related articles for article (PubMed ID: 16598760)

  • 1. Exclusive mutation in epidermal growth factor receptor gene, HER-2, and KRAS, and synchronous methylation of nonsmall cell lung cancer.
    Suzuki M; Shigematsu H; Iizasa T; Hiroshima K; Nakatani Y; Minna JD; Gazdar AF; Fujisawa T
    Cancer; 2006 May; 106(10):2200-7. PubMed ID: 16598760
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The methylation status and protein expression of CDH1, p16(INK4A), and fragile histidine triad in nonsmall cell lung carcinoma: epigenetic silencing, clinical features, and prognostic significance.
    Nakata S; Sugio K; Uramoto H; Oyama T; Hanagiri T; Morita M; Yasumoto K
    Cancer; 2006 May; 106(10):2190-9. PubMed ID: 16598757
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Protein overexpression and gene amplification of epidermal growth factor receptor in nonsmall cell lung carcinomas. An immunohistochemical and fluorescence in situ hybridization study.
    Suzuki S; Dobashi Y; Sakurai H; Nishikawa K; Hanawa M; Ooi A
    Cancer; 2005 Mar; 103(6):1265-73. PubMed ID: 15712203
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Molecular characterization of chronic obstructive pulmonary disease-related non-small cell lung cancer through aberrant methylation and alterations of EGFR signaling.
    Suzuki M; Wada H; Yoshino M; Tian L; Shigematsu H; Suzuki H; Alaa M; Tamura H; Fujiwara T; Nagato K; Motohashi S; Moriya Y; Hoshino H; Yoshida S; Shibuya K; Hiroshima K; Nakatani Y; Yoshino I
    Ann Surg Oncol; 2010 Mar; 17(3):878-88. PubMed ID: 19841986
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Synchronous alterations of Wnt and epidermal growth factor receptor signaling pathways through aberrant methylation and mutation in non small cell lung cancer.
    Suzuki M; Shigematsu H; Nakajima T; Kubo R; Motohashi S; Sekine Y; Shibuya K; Iizasa T; Hiroshima K; Nakatani Y; Gazdar AF; Fujisawa T
    Clin Cancer Res; 2007 Oct; 13(20):6087-92. PubMed ID: 17947472
    [TBL] [Abstract][Full Text] [Related]  

  • 6. EGFR, ERBB2, and KRAS mutations in Korean non-small cell lung cancer patients.
    Bae NC; Chae MH; Lee MH; Kim KM; Lee EB; Kim CH; Park TI; Han SB; Jheon S; Jung TH; Park JY
    Cancer Genet Cytogenet; 2007 Mar; 173(2):107-13. PubMed ID: 17321325
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Patterns of EGFR, HER2, TP53, and KRAS mutations of p14arf expression in non-small cell lung cancers in relation to smoking history.
    Mounawar M; Mukeria A; Le Calvez F; Hung RJ; Renard H; Cortot A; Bollart C; Zaridze D; Brennan P; Boffetta P; Brambilla E; Hainaut P
    Cancer Res; 2007 Jun; 67(12):5667-72. PubMed ID: 17575133
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Reversed mutation rates of KRAS and EGFR genes in adenocarcinoma of the lung in Taiwan and their implications.
    Wu CC; Hsu HY; Liu HP; Chang JW; Chen YT; Hsieh WY; Hsieh JJ; Hsieh MS; Chen YR; Huang SF
    Cancer; 2008 Dec; 113(11):3199-208. PubMed ID: 18932251
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Mutations of the epidermal growth factor receptor gene in lung cancer: biological and clinical implications.
    Kosaka T; Yatabe Y; Endoh H; Kuwano H; Takahashi T; Mitsudomi T
    Cancer Res; 2004 Dec; 64(24):8919-23. PubMed ID: 15604253
    [TBL] [Abstract][Full Text] [Related]  

  • 10. CpG island methylator phenotype involving tumor suppressor genes located on chromosome 3p in non-small cell lung cancer.
    Liu Z; Zhao J; Chen XF; Li W; Liu R; Lei Z; Liu X; Peng X; Xu K; Chen J; Liu H; Zhou QH; Zhang HT
    Lung Cancer; 2008 Oct; 62(1):15-22. PubMed ID: 18358560
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Somatic mutations of the HER2 kinase domain in lung adenocarcinomas.
    Shigematsu H; Takahashi T; Nomura M; Majmudar K; Suzuki M; Lee H; Wistuba II; Fong KM; Toyooka S; Shimizu N; Fujisawa T; Minna JD; Gazdar AF
    Cancer Res; 2005 Mar; 65(5):1642-6. PubMed ID: 15753357
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Distinct epidermal growth factor receptor and KRAS mutation patterns in non-small cell lung cancer patients with different tobacco exposure and clinicopathologic features.
    Tam IY; Chung LP; Suen WS; Wang E; Wong MC; Ho KK; Lam WK; Chiu SW; Girard L; Minna JD; Gazdar AF; Wong MP
    Clin Cancer Res; 2006 Mar; 12(5):1647-53. PubMed ID: 16533793
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Potential clinical significance of a plasma-based KRAS mutation analysis in patients with advanced non-small cell lung cancer.
    Wang S; An T; Wang J; Zhao J; Wang Z; Zhuo M; Bai H; Yang L; Zhang Y; Wang X; Duan J; Wang Y; Guo Q; Wu M
    Clin Cancer Res; 2010 Feb; 16(4):1324-30. PubMed ID: 20145159
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Influence of epidermal growth factor receptor (EGFR) gene mutations on the expression of EGFR, phosphoryl-Akt, and phosphoryl-MAPK, and on the prognosis of patients with non-small cell lung cancer.
    Sonobe M; Nakagawa M; Takenaka K; Katakura H; Adachi M; Yanagihara K; Otake Y; Wada H; Tanaka F
    J Surg Oncol; 2007 Jan; 95(1):63-9. PubMed ID: 17192868
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinical significance of aberrant methylation of prostaglandin E receptor 2 (PTGER2) in nonsmall cell lung cancer: association with prognosis, PTGER2 expression, and epidermal growth factor receptor mutation.
    Tian L; Suzuki M; Nakajima T; Kubo R; Sekine Y; Shibuya K; Hiroshima K; Nakatani Y; Fujisawa T; Yoshino I;
    Cancer; 2008 Sep; 113(6):1396-403. PubMed ID: 18666211
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Hypermethylation of FHIT as a prognostic marker in nonsmall cell lung carcinoma.
    Maruyama R; Sugio K; Yoshino I; Maehara Y; Gazdar AF
    Cancer; 2004 Apr; 100(7):1472-7. PubMed ID: 15042681
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Abnormalities of epidermal growth factor receptor in lung squamous-cell carcinomas, adenosquamous carcinomas, and large-cell carcinomas: tyrosine kinase domain mutations are not rare in tumors with an adenocarcinoma component.
    Ohtsuka K; Ohnishi H; Fujiwara M; Kishino T; Matsushima S; Furuyashiki G; Takei H; Koshiishi Y; Goya T; Watanabe T
    Cancer; 2007 Feb; 109(4):741-50. PubMed ID: 17238183
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Mutational and epigenetic evidence for independent pathways for lung adenocarcinomas arising in smokers and never smokers.
    Toyooka S; Tokumo M; Shigematsu H; Matsuo K; Asano H; Tomii K; Ichihara S; Suzuki M; Aoe M; Date H; Gazdar AF; Shimizu N
    Cancer Res; 2006 Feb; 66(3):1371-5. PubMed ID: 16452191
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Methylation of multiple genes as a candidate biomarker in non-small cell lung cancer.
    Zhang Y; Wang R; Song H; Huang G; Yi J; Zheng Y; Wang J; Chen L
    Cancer Lett; 2011 Apr; 303(1):21-8. PubMed ID: 21255913
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Molecular changes of epidermal growth factor receptor (EGFR) and KRAS and their impact on the clinical outcomes in surgically resected adenocarcinoma of the lung.
    Kim YT; Kim TY; Lee DS; Park SJ; Park JY; Seo SJ; Choi HS; Kang HJ; Hahn S; Kang CH; Sung SW; Kim JH
    Lung Cancer; 2008 Jan; 59(1):111-8. PubMed ID: 17904685
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.